Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan vs ramipril in ischemic heart failure with mid-range ejection fraction
2020-005302-26Phase 3Active
- Sponsor
- St. John Paul II Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in heart failure with mid-range ejection fraction (HFmrEF), heart failure (HF) and ischaemic cardiomyopathy (ICM) comparing Sacubitril/valsartan arm with Ramipril arm (2 arms). Primary endpoint: Change in left ventricular end-systolic volume. Started Jun 2022; status: active.
02
Drugs
sacubitril + valsartanramipril
03
Conditions
heart failure with mid-range ejection fraction (HFmrEF)heart failure (HF)ischaemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on 2020-005302-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005302-26.